MA
BCTXL

MYDA Advisors’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

MYDA Advisors’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Sell
195,821
-4,179
-2% -$3.86K 0.03% 162
2026
Q1 		$206K Buy
+200,000
New +$212K 0.03% 139

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

MYDA Advisors's BCTXL Position: Q2 2026 in Review

MYDA Advisors reduced its BriaCell Therapeutics Warrant (BCTXL) stake by 2.1% in Q2 2026, selling an estimated $3.86K and leaving 195,821 shares worth $174K. The position accounts for 0.03% of the portfolio, ranked #162.

MYDA Advisors first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $206K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • MYDA Advisors held 195,821 shares of BriaCell Therapeutics Warrant worth $174K as of Q2 2026.
  • MYDA Advisors sold 4,179 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $3.86K.
  • BriaCell Therapeutics Warrant made up 0.03% of MYDA Advisors's portfolio in Q2 2026, its #162 holding.
  • MYDA Advisors first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • MYDA Advisors's BriaCell Therapeutics Warrant position peaked at $206K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on MYDA Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.